PLEXISION, INC.
PITSBURG, PA

    /    Who We are Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the Pleximmune Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh.     /    Who We are Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the Pleximmune Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision customizes antigen-specific and non-specific cell-based assays for drug development services in the following categories: Plexision's cellular assays simulate disease, and generate test outputs, which are normalized to the individual, enabling personalized disease-risk assessment. Rajeev Sindhi is the Co-founder of Plexision, Chief Executive Officer, and Chairman of Plexision’s Board of Directors, and Managing Director of the Sandor group of companies in India. He has been in the healthcare business for the last 20 years. The Sandor group is a distribution partner for multinationals such as Sanofi, Abbott and Cantel, and provides diagnostic and scientific services in genetics and genomics in India. The flagship company of the group, Sandor Medicaids Pvt. Ltd serves more than 2500 hospitals in India and South East Asia. Rakesh Sindhi is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer, and a member of Plexision’s Board of Directors. He is also Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of Pediatric Transplant Research at the University of Pittsburgh, where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Rakesh has authored 15 patents/patent applications, and has also authored or co-authored over 130 peer reviewed papers. He has received several grants from the National Institutes of Health to study the immunogenetic basis of transplant rejection, and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children. Ashok Reddy is Director of Operations and has been with Plexision since 2008. He has worked for over three decades in senior management positions, specializing in all aspects of operations. This experience includes personnel management, contract and labor negotiations, client relationships, operational analysis, budgeting, process re-engineering and workflow optimization. In the last two decades Ashok has also held operational roles in the information technology and healthcare IT space. He previously worked as the Senior Vice-President of Operations at Infinite Computer Solutions for over a decade before co-founding IQGateway, a predictive analytics company, where he served as the Chief Operating Officer. Ashok also serves as a consultant to Infinite Healthcare Solutions, a company focused on helping veterans. Rajeev Sindhi is the Co-founder of Plexision, Chairman of Plexision’s Board of Directors, and Managing Director of the Sandor group of companies in India. He has been in the healthcare business for the last 20 years. The Sandor group is a distribution partner for multinationals such as Sanofi, Abbott and Cantel, and provides diagnostic and scientific services in genetics and genomics in India. The flagship company of the group, Sandor Medicaids Pvt. Ltd serves more than 2500 hospitals in India and South East Asia. Mr Reddy is an entrepreneur and engineer who co-founded Shanta Biotechnics, a recombinant vaccine and therapeutic protein manufacturer, which was acquired by Sanofi-Aventis recently. His company has supplied vaccine products for several large-scale national and international vaccination projects conducted under the auspices of the Government of India and the World Health Organization. Mr Reddy currently serves as a Director of Sanofi-Aventis, India. Previously, he worked as a Research scientist for Defence Electronics Research Laboratories, and subsequently, at the Andhra Pradesh Industrial Development Corporation, Hyderabad, India. He is an engineering graduate from the Andhra University, and holds an MBA from Osmania University of Hyderabad, India Dr. Higgs is the Bioinformatics Group Lead within Translational Sciences at MedImmune, focusing on biomarker discovery and development to enhance drug development. Prior to this, he was a Senior Scientist at MITRE, a federally funded R&D company working for the Department of Defense, where he lead epidemiological integration for the CDC and developed detection approaches for biothreats and syndromic surveillance. Previously, he was a Biostatistician at Gene Logic, where he developed predictive models of toxicity. He is adjunct faculty in the Bioinformatics Graduate program at Johns Hopkins University and received his PhD in Bioinformatics and Computational Biology from George Mason University, his MS in Bioinformatics from Johns Hopkins University, and his BS in Biochemistry from Indiana University. test determines whether the transplanted organ is eliciting an increased immune response from the transplant recipient. This type of immune response occurs during transplant rejection, and can be measured in a type of white blood cell called the T-cytotoxic memory lymphocyte. When present, this increased immune response tells your healthcare provider whether transplant rejection is likely or not. Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post- marketing.